Tag Archive for: Elicio Therapeutics

In addition to becoming a Nasdaq-listed company, the focus of Elicio moving forward will be a therapeutic cancer vaccine candidate that targets mKRAS-driven tumors.

Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.